All Releases
 |
Mylan Rebukes and Cites Flaws in Bayer-Sponsored Mylan-Nifedipine Extended Release Bioequivalence Study in Canada
Mar 9, 2010
|
7.6 KB |
|
| |
TORONTO, Mar 9, 2010 (Canada NewsWire via COMTEX News Network) -- Mylan (Nasdaq: MYL) today reported that it has identified multiple flaws within a purported bioequivalence study sponsored by Bayer Inc. of Canada. The study compared Bayer's antihypertensive Adalat(R) XL(R) tablets, 60 mg, marketed in Canada, to Mylan's approved generic version, Myl...
|
|
Moody's Upgrades Mylan
Mar 5, 2010
|
7.2 KB |
|
| |
PITTSBURGH, March 5, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today reported that Moody's Investors Service upgraded the company's credit ratings, including the "Corporate Family Rating" to Ba3 from B1 and the senior secured bank rating to Ba2 from Ba3. Moody's also affirmed Mylan's SGL-1 Speculative Grade Liquidity Rat...
|
|
Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2009
Mar 2, 2010
|
6.5 KB |
|
| |
PITTSBURGH, March 2, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2009, as filed with the U.S. Securities and Exchange Commission on Feb. 26, 2010, is available through its Web site (www.myla...
|
|
Mylan Receives Approval for Generic Version of Actigall(R)
Mar 2, 2010
|
6.3 KB |
|
| |
PITTSBURGH, March 2, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ursodiol Capsules USP, 300 mg, the generic version of Watson's gastroin...
|
|
Mylan Names John D. Sheehan Chief Financial Officer
Feb 25, 2010
|
7.3 KB |
|
| |
PITTSBURGH, Feb 25, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of John D. Sheehan as Executive Vice President and Chief Financial Officer.
Sheehan has nearly 30 years of professional experience in global corporate finance, accounting, auditing and management. He currently serves as CFO fo...
|
|
Mylan Reports Adjusted Diluted EPS of $0.33 for the Quarter and $1.30 for the Year Ended Dec. 31, 2009
Feb 25, 2010
|
30.8 KB |
|
| |
PITTSBURGH, Feb 25, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and twelve months ended December 31, 2009.
Financial Highlights
Adjusted diluted earnings per share (EPS) of $0.33 and $1.30 for the three and twelve months ended December 31, 2009, compared to $0.26 and $...
|
|
Mylan Awarded NABP-VAWD Accreditation for Its Primary North American Distribution Facility
Feb 9, 2010
|
6.8 KB |
|
| |
PITTSBURGH, Feb 09, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Greensboro, N.C., distribution facility has received Verified-Accredited Wholesale Distributors(R) (VAWD) accreditation from the National Association of Boards of Pharmacy(R) (NABP). The NABP established the VAWD program in 2004 to he...
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
Feb 4, 2010
|
7.4 KB |
|
| |
PITTSBURGH, Feb 04, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, 5...
|
|
Mylan Schedules Fourth Quarter 2009 Financial Results Conference Call and Live Webcast
Feb 2, 2010
|
6.6 KB |
|
| |
PITTSBURGH, Feb 02, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thursday, Feb. 25, 2010, at 10 a.m. ET, to review the company's financial results for the fourth quarter 2009, which ended Dec. 31, 2009. Mylan will release its financial results on Feb. ...
|
|
Mylan Receives Approval for Generic Version of GoLytely(R)
Jan 29, 2010
|
6.3 KB |
|
| |
PITTSBURGH, Jan 29, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350 and Electrolytes for Oral Solution, USP, the g...
|
|
Mylan Declares Quarterly Preferred Stock Dividend
Jan 20, 2010
|
6.0 KB |
|
| |
PITTSBURGH, Jan 20, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on ...
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Sleep-Disorder Drug Nuvigil(R)
Jan 11, 2010
|
7.4 KB |
|
| |
PITTSBURGH, Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Cephalon Inc. and Cephalon France in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Armodafinil Tablets, 50 mg, 150 mg and 250 mg. Armodafinil T...
|
|
Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
Jan 8, 2010
|
6.4 KB |
|
| |
PITTSBURGH, Jan 08, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that, in late December 2009, the company pre-paid $196 million in bank term-loan borrowings that were due in 2011. As a result, the company has no term-loan obligations coming due until 2012.
Mylan Chairman and CEO Robert J. Coury said: "The ...
|
|
Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets
Dec 22, 2009
|
7.3 KB |
|
| |
PITTSBURGH, Dec 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efav...
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
Dec 22, 2009
|
7.6 KB |
|
| |
PITTSBURGH, Dec 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Schering Corporation and MSP Singapore Company in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Ad...
|
|
Mylan to Sponsor PGA TOUR's Nationwide Tour Event at Southpointe Golf Club in Early September
Dec 17, 2009
|
7.9 KB |
|
| |
PITTSBURGH, Dec 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that it will sponsor a PGA TOUR Nationwide Tour event -- the Mylan Classic -- at Southpointe Golf Club in the Pittsburgh suburb of Canonsburg in 2010.
Mylan Chairman and CEO Robert J. Coury said: "We are extremely proud to sponsor th...
|
|
Mylan Added to NASDAQ-100 Index
Dec 14, 2009
|
6.8 KB |
|
| |
PITTSBURGH, Dec 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that the company will be added to the NASDAQ-100 Index Dec. 21. Mylan's common shares will also be included in NASDAQ's PowerShares QQQ.
Mylan Chairman and CEO Robert J. Coury said: "We are extremely pleased to join NASDAQ's most wid...
|
|
Mylan Receives Approval for Generic Version of Antiepileptic Keppra® 1000 mg
Dec 11, 2009
|
34.1 KB |
|
| |
PITTSBURGH, Dec 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 1000 mg. Levetiracetam Tablets are the ...
|
|
Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
Dec 8, 2009
|
7.3 KB |
|
| |
PITTSBURGH, Dec 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to Venlafaxine Hydrochloride (HCl) Extended Release (ER) Capsules, 37.5 mg, 75 mg and 150 mg, t...
|
|
Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
Nov 18, 2009
|
7.1 KB |
|
| |
PITTSBURGH, Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that Didier Barret, president of Mylan Europe, Middle East and Africa (EMEA), has been elected president of the European Generic Medicines Association (EGA). Barret was elected to a two-year term earlier today at the EGA annual meetin...
|
|
|
